Compare BANR & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANR | NUVB |
|---|---|---|
| Founded | 1890 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2015 | 2020 |
| Metric | BANR | NUVB |
|---|---|---|
| Price | $70.46 | $6.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $70.00 | $11.38 |
| AVG Volume (30 Days) | 290.3K | ★ 5.5M |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | 15.57 | ★ 71.56 |
| EPS | ★ 3.03 | N/A |
| Revenue | N/A | ★ $62,902,000.00 |
| Revenue This Year | $0.73 | $203.82 |
| Revenue Next Year | $5.69 | $58.18 |
| P/E Ratio | $23.16 | ★ N/A |
| Revenue Growth | N/A | ★ 698.96 |
| 52 Week Low | $57.05 | $2.91 |
| 52 Week High | $74.84 | $9.75 |
| Indicator | BANR | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 47.58 | 53.61 |
| Support Level | $62.40 | $5.28 |
| Resistance Level | $72.65 | $6.80 |
| Average True Range (ATR) | 1.26 | 0.35 |
| MACD | -0.40 | -0.00 |
| Stochastic Oscillator | 20.07 | 52.37 |
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho, and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.